Innoviva vs Mirum Pharmaceuticals
Mirum Pharmaceuticals reported revenue of $521 million in fiscal 2025, 1.3 times Innoviva's $411 million in fiscal 2025. Innoviva's revenue grew 14.7% in its latest year, and Mirum Pharmaceuticals' grew 54.7%. Innoviva had an operating margin of 39.8%, against -4.2% at Mirum Pharmaceuticals. Free cash flow was $196 million at Innoviva and $55 million at Mirum Pharmaceuticals.
Side by side
| Innoviva | Mirum Pharmaceuticals | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $411M | $521M |
| Revenue growth | 14.7% | 54.7% |
| Revenue growth a year, last 5 years | 4.1% | — |
| Gross margin | 74.8% | — |
| Operating margin | 39.8% | −4.2% |
| Net margin | 65.9% | −4.5% |
| Free cash flow | $196M | $55M |
| Free cash flow margin | 47.6% | 10.5% |
| Return on capital | 17.9% | −7.1% |
| Net debt to EBITDA | — | −34.9x |
| Dividends and buybacks | $4M | $0M |
| Change in diluted share count | 14.2% | 5.6% |
| Last close | $19.03 | $93.99 |
| P/E at the last close | 9.5× | — |
| Insider trades, last 12 months | — | bought $9.0 million, sold $42.9 million |
| Piotroski F-score | 6 of 9 | 5 of 8 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
InnovivaMirum Pharmaceuticals
Operating margin
Percent of revenue
InnovivaMirum Pharmaceuticals
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
InnovivaMirum Pharmaceuticals
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Innoviva and Mirum Pharmaceuticals pages.